ACXP Acurx Pharmaceuticals, Inc.

Nasdaq www.acurxpharma.com


$ 7.57 $ 0.43 (6.01 %)    

Tuesday, 14-Oct-2025 18:13:38 EDT
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 7.59
$ 7.14
$ 6.80 x 1
$ 7.98 x 15
$ 6.97 - $ 7.87
$ 3.80 - $ 41.64
171,691
na
12.03M
nm
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-17-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-15-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-15-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-16-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-13-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 acurx-pharma-secures-australian-patent-for-dna-polymerase-iiic-inhibitors-expanding-acx-375c-coverage-across-five-countries

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company de...

 hc-wainwright--co-reiterates-buy-on-acurx-pharmaceuticals-maintains-31-price-target

HC Wainwright & Co. analyst Matthew Keller reiterates Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and maintains $31 p...

 acurx-pharma-receives-favorable-opinion-from-pdco-of-ema-on-acurxs-pediatric-investigation-plan-for-ibezapolstat-use-in-children-with-c-difficile-infection

The Paediatric Committee (PDCO) of the European Medicines Agency issued a positive opinion on Acurx's Pediatric Investigati...

 hc-wainwright--co-maintains-buy-on-acurx-pharmaceuticals-raises-price-target-to-31

HC Wainwright & Co. analyst Matthew Keller maintains Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and raises the price...

 acurx-pharmaceuticals-q2-eps-189-up-from-521-yoy

Acurx Pharmaceuticals (NASDAQ:ACXP) reported Q2 EPS $(1.89) Up from $(5.21) YoY

 acurx-pharmaceuticals-announces-1-for-20-reverse-stock-split-trading-post-split-on-august-5-2025

Acurx's common stock is expected to begin trading on a post-split adjusted basis on August 5, 2025STATEN ISLAND, N.Y., July...

 acurx-pharmaceuticals-files-for-mixed-shelf-of-up-to-50m

-SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION